Motor Imagery Intervention for Improving Gait and Cognition in the Elderly
NCT02762604, Not applicable, Completed, Albert Einstein College of Medicine; results first posted 2024-06-04
Trial 11
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Motor Imagery Intervention for Improving Gait and Cognition in the Elderly | ClinicalTrials.gov |
| NCT number | NCT02762604 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 49 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Albert Einstein College of Medicine | ClinicalTrials.gov |
| Conditions | Motor Activity | ClinicalTrials.gov |
| Interventions | Imagined Gait Intervention, Visual Imagery Intervention | ClinicalTrials.gov |
| First posted | 2016-05-05 | ClinicalTrials.gov |
| Last updated | 2024-06-04 | ClinicalTrials.gov |
| Results first posted | 2024-06-04 | ClinicalTrials.gov |
Registered outcomes 26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Walking Speed During Single and Dual-task Walking Conditions | Baseline and 3 months | Change in gait speed (centimeters per second) measured during normal pace walking and walking while talking conditions using an instrumented pathway. A positive mean value is indicative of an improvement (increase) in gait speed post-intervention, whereas a negative mean value is indicative of a decrease in gait speed post-intervention. | ClinicalTrials.gov |
| Secondary | Change in Cognitive Performance During Walking While Talking | Baseline and 3 months | Change in cognitive performance was assessed by the number of correct letters/time (in seconds) generated during walking while talking (WWT). This exercise consists of having the participant walk around a computerized walkway while reciting alternate letters of the alphabet (WWT), starting with the letter "B." A positive mean value reflects an improvement in cognitive performance (increase in the number of correct letters/time generated) post-intervention; whereas, a negative mean value reflects worsening in cognitive performance (decrease in the number of correct letters/time generated) post-intervention. | ClinicalTrials.gov |
| Secondary | Change in Blood-oxygen-level-dependent (BOLD) Signal During Dual-task Imagined Walking While Talking (iWWT) Conditions | Baseline and 3 months | Change in blood-oxygen-level-dependent (BOLD) signal (neuroplasticity) during imagined walking and walking while talking (iWWT) conditions were measured using functional magnetic resonance imaging (fMRI). The mean values reported are changes in factor scores that reflect the overall change in BOLD signal pre- to post-intervention. Positive values reflect an increase in BOLD signal post-intervention, whereas, negative mean values reflect a decrease in BOLD signal post intervention. There are no minimum or maximum values or ranges or thresholds associated with the BOLD measure. | ClinicalTrials.gov |
| Secondary | Change in Trail Making Test Form A | Baseline and 3 months | Change in Trail Making Test Form A (TMT-A), is a timed measurement of attention and processing speed. Scoring is based on the time required to complete the task (i.e., drawing a line between 24 consecutive circles randomly arranged on a page) and ranges from 0-300 seconds with shorter time indicating better performance. A negative mean difference reflects an improvement pre to post intervention. The TMT-A uses all numbers (no letters) and includes correction of errors prompted by the examiner. | ClinicalTrials.gov |
| Secondary | Change in Trail Making Test Form B | Baseline and 3 months | Change in Trail Making Test, Form B (TMT-B), is a timed measurement of attention, processing speed, and set-shifting. Scoring is based on the time required to complete the task (i.e., drawing a line between 24 consecutive circles randomly arranged on a page) and ranges from 0-300 seconds with shorter times indicating better performance. A negative mean difference reflects an improvement pre to post intervention. The TMT-B alternates between numbers and letters requiring the participant to switch between numbers and letters in consecutive order and includes correction of errors prompted by the examiner. | ClinicalTrials.gov |
| Secondary | Change in Trail Making Test Form B Minus Form A | Baseline and 3 months | Change in Trail Making Test Form B (TMT-B) minus Form A (TMT-A), a timed measure of set-shifting. Scoring is based on the change in time between completing Form B compared to Form A. A negative mean difference reflects an improvement post intervention. | ClinicalTrials.gov |
| Secondary | Change in Letter Number Sequencing Task Score | Baseline and 3 months | Change in scoring in the letter number sequencing task, a measure of item manipulation, was derived from the letter number sequencing subtest of the working memory domain within the Wechsler Adult Intelligence Scale (WAIS) III battery, a widely used intelligence test for adults. Scoring is based on the number of correctly sequenced letters and numbers with increasing (positive) mean scores indicating an improvement in task performance post intervention. A negative mean score reflects a decrease in task performance post intervention. | ClinicalTrials.gov |
| Secondary | Change in Stroop Interference Test: Color-Word Minus Color Score | Baseline and 3 months | Change in Stroop Interference Test: Color-Word (incongruent trials) minus Color (congruent trials) scores were determined. It is a measure of response competition and interference. Scoring is based on the time it takes to read (complete) incongruent trials relative to congruent trials. A negative mean value reflects an improvement in performance after the intervention. A positive mean value reflects an decrease in performance after the intervention. | ClinicalTrials.gov |
| Secondary | Change in Flanker Interference Task | Baseline and 3 months | Change in the Flanker Interference Task measures how much interference is generated by the presentation of adjacent incongruent and congruent visual information. Scoring is based on the difference in reaction time (in milliseconds) between incongruent and congruent trials responded to correctly. A negative mean is indicative of improved interference post intervention and a positive mean value is indicative of worsening interference post intervention. | ClinicalTrials.gov |
| Secondary | Change in Stride Length | Baseline and 3 months | Change in stride length were collected during walking while talking (WWT) conditions on an instrumented walkway. Stride length was defined as the distance between the heel points of 2 consecutive footfalls of the same foot and measured in centimeters (cm). | ClinicalTrials.gov |
| Secondary | Change in Gait Variability | Baseline and 3 months | Change in gait variability is collected during walking while talking on an instrumented walkway. Gait variability, defined as the stride-to-stride fluctuations in walking, was measured by the coefficient of variation (CV) of the mean value of stride-to stride time. CV reflects the level of gait rhythmicity, with lower values indicating greater rhythmicity. A negative mean CV reflects improved (less) variability post intervention whereas a positive mean CV value reflects worse (increased) variability. Stride time CV is closely associated with falls | ClinicalTrials.gov |
| Secondary | Change in Gait Domains | Baseline and 3 months | Change in gait domains (summary measures reported in standard deviation units) derived from factor analysis of quantitative gait variables collected on an instrumented walkway during normal pace walking and walking while talking. Gait domain score is calculated by summing ratings for individual items and dividing by the maximum possible score for the domain, then multiplying by 100. The domain score ranges from 0 to 100, with higher scores reflecting more gait disturbance and lower scores reflecting less gait disturbance. | ClinicalTrials.gov |
| Other | Change in Free Cued Serial Recall Test | Baseline and 3 months | Changes in free recall performance were based on the free cued serial recall test, a measure of verbal learning and memory. Scores range from 0 to 48. Mean values reflect the change in the number of items recalled pre and post intervention. A positive mean value indicates improved recall performance post intervention whereas a negative mean value reflects decreased performance post intervention. | ClinicalTrials.gov |
| Other | Change in Delayed Figure Copy Recall on Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | Baseline and 3 months | Change in delayed figure copy recall performance from the RBANS assessment, a measure of spatial learning and memory. Figure copy recall scores range from 0 to 20. A positive mean is indicative of an increase in recall post intervention whereas a negative mean is indicative of a decrease in recall post intervention. | ClinicalTrials.gov |
| Other | Change in Controlled Oral Word Fluency Test | Baseline and 3 months | Change in the number of correct words generated on the controlled oral word fluency test, a measure of language processing. Scores range from 0 to 36. A positive mean reflects an improvement in language processing post intervention whereas a negative mean reflects worsening of language processing post intervention | ClinicalTrials.gov |
| Other | Change in Semantic Fluency Test | Baseline and 3 months | Change in the total number of correct words generated for each category on the semantic fluency test, a measure of language processing. Scores reflect the number of correct items generated in a 60 second window. A positive mean value reflects improved semantic fluency post intervention and a negative mean value reflects worsening of semantic fluency post intervention. | ClinicalTrials.gov |
| Other | Change in Digit Symbol Substitution | Baseline and 3 months | Change in number of correct digit symbols generated on the digit symbol substitution test (DSST), a measure of processing speed, attention and working memory. The number of correct symbols within the allowed time in seconds is measured. A positive mean reflects an improvement in the number of correct digit symbols generated post intervention whereas a negative mean value reflects fewer correct digits generated post intervention. | ClinicalTrials.gov |
| Other | Modified Short Physical Performance Battery (SPPB) at Baseline | Baseline | SPPB is a measure of lower extremity function and includes a balance test, a chair stand test and a gait speed test. Because gait speed/velocity was our primary outcome, only administered the balance and chair stand tests were administered. Thus, possible scores range from 0-8 (rather than the typical 0-12) with 0 being worst performance and 8 being best performance. | ClinicalTrials.gov |
| Other | Change in Immediate Maze Task Performance | Baseline and 3 months | Change in mean immediate maze performance (time in seconds), a measure of spatial navigation and memory, were determined. A negative mean value represents an improvement in immediate maze performance post intervention whereas a positive mean value represents worsening of maze performance post intervention. | ClinicalTrials.gov |
| Other | Change in Delayed Maze Task Performance | Baseline and 3 months | Change in mean delayed maze performance (time in seconds), a measurement of spatial navigation and memory, were determined. A negative mean value represents an improvement in delayed maze performance post intervention, whereas a positive mean performance time represents worsening delayed maze performance post intervention | ClinicalTrials.gov |
Outcomes 26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|---|---|---|---|---|---|
| PRIMARY | Change in Walking Speed During Single and Dual-task Walking Conditions | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | centimeters per second | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Cognitive Performance During Walking While Talking | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 2 participants in the Visual Imagery group and 7 participants in the Imagined Gait group due to missing data. | correct letters/second | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Blood-oxygen-level-dependent (BOLD) Signal During Dual-task Imagined Walking While Talking (iWWT) Conditions | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 2 participants in the Visual Imagery group and 2 participants in the Imagined Gait group due to incomplete tasks/sessions or corrupted data files. | Factor score for BOLD signal | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Trail Making Test Form A | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Trail Making Test Form B | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Trail Making Test Form B Minus Form A | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Letter Number Sequencing Task Score | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | Correct sequences | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Stroop Interference Test: Color-Word Minus Color Score | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure) and for 1 participant in the Imagined Gait group due to missing data. | seconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Flanker Interference Task | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 7 participants in the Visual Imagery Group and 13 participants in the Imagined Gait group due to incomplete tasks/sessions or corrupted data files. | milliseconds | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Stride Length | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 1 participant in the Visual Imagery group and 6 participants in the Imagined Gait group due to missing data or corrupted data files. | centimeters | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Gait Variability | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 1 participant in the Visual Imagery group and 6 participants in the Imagined Gait group due to missing data or corrupted data files. | Coefficient of Variation (CV) | MEAN | ClinicalTrials.gov |
| SECONDARY | Change in Gait Domains | Baseline and 3 months | Data were unable to be accurately computed for Gait Domain outcome measure due to incomplete data collection of the individual gait variable measurements which would have been summed to generate a Gait Domain Score. Since there was not enough data overall for the models to converge Gait Domain data was not able to be collected. | ClinicalTrials.gov | ||
| OTHER_PRE_SPECIFIED | Change in Free Cued Serial Recall Test | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | correct items recalled | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Change in Delayed Figure Copy Recall on Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | correct items recalled | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Change in Controlled Oral Word Fluency Test | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | correct items generated | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Change in Semantic Fluency Test | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). | correct words/minute | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Change in Digit Symbol Substitution | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Please note that data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 1 participant in the Imagined Gait group due to missing data. | correct digit symbols | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Modified Short Physical Performance Battery (SPPB) at Baseline | Baseline | SPPB was only administered at baseline (only the balance and chair tests were administered). Change analyses were not performed. | score on a scale | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Change in Immediate Maze Task Performance | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 5 participants in the in the Imagined Gait group due to missing data. | seconds | MEAN | ClinicalTrials.gov |
| OTHER_PRE_SPECIFIED | Change in Delayed Maze Task Performance | Baseline and 3 months | Overall number of participants analyzed includes all randomized participants with baseline measures. Data was unable to be analyzed for 14 participants in the Visual Imagery group due to a protocol deviation (incorrect intervention procedure). Data was also unable to be analyzed for 4 participants in the in the Imagined Gait group due to missing data. | seconds | MEAN | ClinicalTrials.gov |
Results by group 48
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|---|---|---|---|---|---|
| Change in Walking Speed During Single and Dual-task Walking Conditions | Imagined Gait Intervention | Gait speed (normal pace) | -3.33 | Standard Deviation 14.13 | centimeters per second | ClinicalTrials.gov |
| Change in Walking Speed During Single and Dual-task Walking Conditions | Visual Imagery Intervention | Gait speed (normal pace) | -0.53 | Standard Deviation 25.77 | centimeters per second | ClinicalTrials.gov |
| Change in Walking Speed During Single and Dual-task Walking Conditions | Imagined Gait Intervention | Gait speed (walking-while-talking) | 5.89 | Standard Deviation 20.44 | centimeters per second | ClinicalTrials.gov |
| Change in Walking Speed During Single and Dual-task Walking Conditions | Visual Imagery Intervention | Gait speed (walking-while-talking) | -10.55 | Standard Deviation 15.68 | centimeters per second | ClinicalTrials.gov |
| Change in Cognitive Performance During Walking While Talking | Imagined Gait Intervention | 0.19 | Standard Deviation 1.46 | correct letters/second | ClinicalTrials.gov | |
| Change in Cognitive Performance During Walking While Talking | Visual Imagery Intervention | -1.54 | Standard Deviation 1.50 | correct letters/second | ClinicalTrials.gov | |
| Change in Blood-oxygen-level-dependent (BOLD) Signal During Dual-task Imagined Walking While Talking (iWWT) Conditions | Imagined Gait Intervention | -2.98 | Standard Deviation 19.35 | Factor score for BOLD signal | ClinicalTrials.gov | |
| Change in Blood-oxygen-level-dependent (BOLD) Signal During Dual-task Imagined Walking While Talking (iWWT) Conditions | Visual Imagery Intervention | -3.07 | Standard Deviation 11.89 | Factor score for BOLD signal | ClinicalTrials.gov | |
| Change in Trail Making Test Form A | Imagined Gait Intervention | -0.72 | Standard Deviation 19.16 | seconds | ClinicalTrials.gov | |
| Change in Trail Making Test Form A | Visual Imagery Intervention | -1.45 | Standard Deviation 5.93 | seconds | ClinicalTrials.gov | |
| Change in Trail Making Test Form B | Imagined Gait Intervention | 4.49 | Standard Deviation 54.18 | seconds | ClinicalTrials.gov | |
| Change in Trail Making Test Form B | Visual Imagery Intervention | -9.54 | Standard Deviation 19.74 | seconds | ClinicalTrials.gov | |
| Change in Trail Making Test Form B Minus Form A | Imagined Gait Intervention | 5.22 | Standard Deviation 50.28 | seconds | ClinicalTrials.gov | |
| Change in Trail Making Test Form B Minus Form A | Visual Imagery Intervention | -8.09 | Standard Deviation 23.09 | seconds | ClinicalTrials.gov | |
| Change in Letter Number Sequencing Task Score | Imagined Gait Intervention | -0.55 | Standard Deviation 2.15 | Correct sequences | ClinicalTrials.gov | |
| Change in Letter Number Sequencing Task Score | Visual Imagery Intervention | 0.61 | Standard Deviation 1.84 | Correct sequences | ClinicalTrials.gov | |
| Change in Stroop Interference Test: Color-Word Minus Color Score | Imagined Gait Intervention | -8.38 | Standard Deviation 30.14 | seconds | ClinicalTrials.gov | |
| Change in Stroop Interference Test: Color-Word Minus Color Score | Visual Imagery Intervention | -14.47 | Standard Deviation 31.37 | seconds | ClinicalTrials.gov | |
| Change in Flanker Interference Task | Imagined Gait Intervention | -49.55 | Standard Deviation 108.85 | milliseconds | ClinicalTrials.gov | |
| Change in Flanker Interference Task | Visual Imagery Intervention | -94.69 | Standard Deviation 93.97 | milliseconds | ClinicalTrials.gov |
Participant flow 6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|---|---|---|---|---|
| Overall Study | STARTED | Imagined Gait Intervention | 25 | ClinicalTrials.gov | |
| Overall Study | STARTED | Visual Imagery Intervention | 24 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Imagined Gait Intervention | 22 | ClinicalTrials.gov | |
| Overall Study | COMPLETED | Visual Imagery Intervention | 14 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Imagined Gait Intervention | 3 | ClinicalTrials.gov | |
| Overall Study | NOT COMPLETED | Visual Imagery Intervention | 10 | ClinicalTrials.gov |
Adverse events 20
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Anemia | Blood and lymphatic system disorders | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
| other | Arthritis | Musculoskeletal and connective tissue disorders | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Arthritis | Musculoskeletal and connective tissue disorders | Visual Imagery Intervention | 2 | 24 | 2 | ClinicalTrials.gov |
| other | Tinnitus | Ear and labyrinth disorders | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Tinnitus | Ear and labyrinth disorders | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
| other | Fall | Musculoskeletal and connective tissue disorders | Imagined Gait Intervention | 1 | 25 | 1 | ClinicalTrials.gov |
| other | Fall | Musculoskeletal and connective tissue disorders | Visual Imagery Intervention | 2 | 24 | 2 | ClinicalTrials.gov |
| other | Back/shoulder pain | Musculoskeletal and connective tissue disorders | Imagined Gait Intervention | 3 | 25 | 5 | ClinicalTrials.gov |
| other | Back/shoulder pain | Musculoskeletal and connective tissue disorders | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
| other | Pain in lower extremities | Musculoskeletal and connective tissue disorders | Imagined Gait Intervention | 1 | 25 | 1 | ClinicalTrials.gov |
| other | Pain in lower extremities | Musculoskeletal and connective tissue disorders | Visual Imagery Intervention | 1 | 24 | 4 | ClinicalTrials.gov |
| other | Pain in upper extremities | Musculoskeletal and connective tissue disorders | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Pain in upper extremities | Musculoskeletal and connective tissue disorders | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
| other | Enlarged prostate | Reproductive system and breast disorders | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Enlarged prostate | Reproductive system and breast disorders | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
| other | Dizziness | Ear and labyrinth disorders | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| other | Dizziness | Ear and labyrinth disorders | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
| serious | Pneumonia | Infections and infestations | Imagined Gait Intervention | 0 | 25 | 0 | ClinicalTrials.gov |
| serious | Pneumonia | Infections and infestations | Visual Imagery Intervention | 1 | 24 | 1 | ClinicalTrials.gov |
Adverse event totals 6
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|---|---|---|---|
| Total, all-cause mortality | Imagined Gait Intervention | 0 | 25 | ClinicalTrials.gov |
| Total, all-cause mortality | Visual Imagery Intervention | 0 | 24 | ClinicalTrials.gov |
| Total, other adverse events | Imagined Gait Intervention | 5 | 25 | ClinicalTrials.gov |
| Total, other adverse events | Visual Imagery Intervention | 11 | 24 | ClinicalTrials.gov |
| Total, serious adverse events | Imagined Gait Intervention | 0 | 25 | ClinicalTrials.gov |
| Total, serious adverse events | Visual Imagery Intervention | 1 | 24 | ClinicalTrials.gov |
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 29165011 | DERIVED | PubMed |
Grants 2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| K01AG049829 | Motor Imagery: A Pilot Intervention for Improving Gait and Cognition in the Elderly | BLUMEN, HELENA M | ALBERT EINSTEIN COLLEGE OF MEDICINE | NATIONAL INSTITUTE ON AGING | 2016 to 2019 | NIH RePORTER |
| KL2TR001071 | Clinical and Translational Science Award | SHAMOON, HARRY | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2013 to 2017 | NIH RePORTER |
Trial comparisons 2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Imagined Gait Intervention vs Visual Imagery Intervention: deaths from any cause | Trial comparisons |
| Imagined Gait Intervention vs Visual Imagery Intervention: serious adverse events | Trial comparisons |
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Other outcome | ConductCognition |
| Letter-Number Sequencing Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Other outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)